Lyka Labs Limited Total Assets
Lyka Labs Limited total assets. Based on the latest financial reports, Lyka Labs Limited (LYKALABS) holds total assets worth Rs1.68 Billion INR (≈ $18.15 Million USD) as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see how much is Lyka Labs Limited worth for the company's overall valuation and market capitalisation.
Total Assets of Lyka Labs Limited (2005–2025)
Total assets of Lyka Labs Limited from 2005 to 2025. This chart illustrates how Lyka Labs Limited's total assets have evolved over time, based on quarterly financial data. See Lyka Labs Limited (LYKALABS) share price today for real-time trading data and today's change.
Lyka Labs Limited - Asset Composition Analysis
Lyka Labs Limited Total Assets Breakdown (March 2025)
Lyka Labs Limited total assets breakdown as of March 2025. Lyka Labs Limited's total assets of Rs1.68 Billion consist of 38.3% current assets and 61.7% non-current assets.
| Asset Category | Amount (INR) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | Rs0.00 | 0.8% |
| Accounts Receivable | Rs431.28 Million | 24.5% |
| Inventory | Rs124.66 Million | 7.1% |
| Property, Plant & Equipment | Rs771.00 Million | 43.8% |
| Intangible Assets | Rs90.42 Million | 5.1% |
| Goodwill | Rs1.78 Million | 0.1% |
Asset Composition Trend (2005–2025)
This chart illustrates how Lyka Labs Limited's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore Lyka Labs Limited short-term liquidity ratio to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Lyka Labs Limited's current assets represent 38.3% of total assets in 2025, a decrease from 74.9% in 2005.
- Cash Position: Cash and equivalents constituted 0.8% of total assets in 2025, up from 0.4% in 2005.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 5.0% of total assets, an increase from 0.0% in 2005.
- Asset Diversification: The largest asset category is property, plant & equipment at 43.8% of total assets.
Lyka Labs Limited Competitors by Total Assets
Key competitors of Lyka Labs Limited based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Madrigal Pharmaceuticals Inc
NASDAQ:MDGL
|
USA | $1.26 Billion |
|
Verona Pharma plc
F:I9SA
|
Germany | €572.87 Million |
|
Centessa Pharmaceuticals PLC ADR
NASDAQ:CNTA
|
USA | $641.76 Million |
|
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252
|
China | CN¥37.46 Billion |
|
Metsera, Inc. Common Stock
NASDAQ:MTSR
|
USA | $639.66 Million |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161
|
China | CN¥16.55 Billion |
|
Bavarian Nordic
CO:BAVA
|
Denmark | Dkr14.95 Billion |
|
Hebei Changshan Biochem Pharma
SHE:300255
|
China | CN¥4.66 Billion |
Lyka Labs Limited - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.41 | 1.48 | 0.51 |
| Quick Ratio | 1.14 | 1.23 | 0.43 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | Rs176.37 Million | Rs189.94 Million | Rs-308.04 Million |
Lyka Labs Limited - Advanced Valuation Insights
This section examines the relationship between Lyka Labs Limited's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 2.31 |
| Latest Market Cap to Assets Ratio | 0.02 |
| Asset Growth Rate (YoY) | 12.4% |
| Total Assets | Rs1.76 Billion |
| Market Capitalization | $29.17 Million USD |
Valuation Analysis
Below Book Valuation: The market values Lyka Labs Limited's assets below their book value (0.02x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: Lyka Labs Limited's assets grew by 12.4% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Lyka Labs Limited (2005–2025)
The table below shows the annual total assets of Lyka Labs Limited from 2005 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-03-31 | Rs1.76 Billion ≈ $19.06 Million |
+12.43% |
| 2024-03-31 | Rs1.57 Billion ≈ $16.95 Million |
+3.43% |
| 2023-03-31 | Rs1.52 Billion ≈ $16.39 Million |
-18.37% |
| 2022-03-31 | Rs1.86 Billion ≈ $20.07 Million |
-2.31% |
| 2021-03-31 | Rs1.90 Billion ≈ $20.55 Million |
-5.07% |
| 2020-03-31 | Rs2.00 Billion ≈ $21.65 Million |
-7.91% |
| 2019-03-31 | Rs2.17 Billion ≈ $23.51 Million |
-7.54% |
| 2018-03-31 | Rs2.35 Billion ≈ $25.42 Million |
-5.37% |
| 2017-03-31 | Rs2.48 Billion ≈ $26.87 Million |
+2.82% |
| 2016-03-31 | Rs2.42 Billion ≈ $26.13 Million |
-13.32% |
| 2015-03-31 | Rs2.79 Billion ≈ $30.15 Million |
-15.34% |
| 2014-03-31 | Rs3.29 Billion ≈ $35.61 Million |
+13.97% |
| 2013-03-31 | Rs2.89 Billion ≈ $31.24 Million |
+2.26% |
| 2012-03-31 | Rs2.83 Billion ≈ $30.55 Million |
-20.60% |
| 2010-03-31 | Rs3.56 Billion ≈ $38.48 Million |
+17.30% |
| 2009-03-31 | Rs3.03 Billion ≈ $32.81 Million |
+64.64% |
| 2008-03-31 | Rs1.84 Billion ≈ $19.93 Million |
+15.39% |
| 2007-03-31 | Rs1.60 Billion ≈ $17.27 Million |
+13.75% |
| 2005-03-31 | Rs1.40 Billion ≈ $15.18 Million |
-- |
About Lyka Labs Limited
Lyka Labs Limited, a pharmaceutical company, develops, manufactures, and markets pharmaceutical formulations and active pharmaceutical ingredients in India. The company manufactures and sells various formulations, including emollient, topical steroid, antifungal agent, topical anti-bacterial, acne management, dermatological formulation, pain killer, anti-aging, cleansing lotion, hair care, anti-d… Read more